ATE515189T1 - Verfahren zur herstellung von antigenspezifischen lymphozyten - Google Patents
Verfahren zur herstellung von antigenspezifischen lymphozytenInfo
- Publication number
- ATE515189T1 ATE515189T1 AT02794219T AT02794219T ATE515189T1 AT E515189 T1 ATE515189 T1 AT E515189T1 AT 02794219 T AT02794219 T AT 02794219T AT 02794219 T AT02794219 T AT 02794219T AT E515189 T1 ATE515189 T1 AT E515189T1
- Authority
- AT
- Austria
- Prior art keywords
- lymphocytes
- cells
- antigen
- generation
- resulting
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33937501P | 2001-12-10 | 2001-12-10 | |
| US39480302P | 2002-07-08 | 2002-07-08 | |
| PCT/US2002/039527 WO2003050262A2 (en) | 2001-12-10 | 2002-12-10 | Method for the generation of antigen-specific lymphocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE515189T1 true ATE515189T1 (de) | 2011-07-15 |
Family
ID=26991603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02794219T ATE515189T1 (de) | 2001-12-10 | 2002-12-10 | Verfahren zur herstellung von antigenspezifischen lymphozyten |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030152559A1 (de) |
| EP (1) | EP1450611B1 (de) |
| AT (1) | ATE515189T1 (de) |
| AU (1) | AU2002359666A1 (de) |
| WO (1) | WO2003050262A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
| US20050238626A1 (en) * | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| EP1627563A1 (de) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Verfahren und Mittel zur Herstellung einer stabilisierten Zelle |
| EP1891209A1 (de) * | 2005-06-06 | 2008-02-27 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Methoden zur herstellung von t-zellen, die mit einem gewünschten antigen reagieren. |
| EP1954811B1 (de) | 2005-11-17 | 2011-06-08 | TET Systems GmbH & Co. KG | Induzierbare expressionssysteme |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| NZ600075A (en) * | 2005-12-09 | 2013-12-20 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| US9005974B2 (en) * | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| EP1878744A1 (de) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren |
| WO2009058012A1 (en) * | 2007-11-01 | 2009-05-07 | Deltacell B.V. | Means and methods for eliciting an immune response |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| EP2454283B1 (de) | 2009-07-15 | 2018-03-14 | AIMM Therapeutics B.V. | Mitteln und verfahren zur produktion von antikörper mit hohe affinität |
| EP3202410B1 (de) | 2010-04-14 | 2020-03-25 | Roger Williams Medical Center | Verfahren und zusammensetzungen zur behandlung von hiv |
| CN103429615B (zh) | 2010-12-02 | 2018-03-16 | 埃姆医疗有限公司 | 用于生产高亲和力抗体的方式和方法 |
| WO2014183056A1 (en) | 2013-05-10 | 2014-11-13 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Design and use of specific regulatory t-cells to induce immune tolerance |
| CA2938193C (en) | 2014-01-31 | 2023-05-02 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
| GB201719169D0 (en) * | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
| US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| US5830755A (en) * | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
-
2002
- 2002-12-10 AU AU2002359666A patent/AU2002359666A1/en not_active Abandoned
- 2002-12-10 WO PCT/US2002/039527 patent/WO2003050262A2/en not_active Application Discontinuation
- 2002-12-10 EP EP02794219A patent/EP1450611B1/de not_active Expired - Lifetime
- 2002-12-10 US US10/317,078 patent/US20030152559A1/en not_active Abandoned
- 2002-12-10 AT AT02794219T patent/ATE515189T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1450611A4 (de) | 2005-12-07 |
| AU2002359666A8 (en) | 2003-06-23 |
| US20030152559A1 (en) | 2003-08-14 |
| EP1450611B1 (de) | 2011-07-06 |
| WO2003050262A2 (en) | 2003-06-19 |
| AU2002359666A1 (en) | 2003-06-23 |
| WO2003050262A3 (en) | 2004-02-12 |
| EP1450611A2 (de) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE515189T1 (de) | Verfahren zur herstellung von antigenspezifischen lymphozyten | |
| Brooks et al. | IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection | |
| JP2013213034A (ja) | パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法 | |
| CY1106785T1 (el) | Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο | |
| DE60139026D1 (de) | Lebender influenza impfstoff und verfahren zu seiner herstellung | |
| CY1113241T1 (el) | Μεθοδος για την παραγωγη ενεργου συστατικου ενος φαρμακευτικου ή διαγνωστικου μεσου εντος καλλιεργειας αιωρηματος κυτταρων mdck | |
| DE69723434D1 (de) | Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope | |
| DK0633929T3 (da) | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener | |
| DE68927348D1 (de) | Künstlicher impfstoff gegen aids-virus | |
| de Aquino et al. | IL-27 limits central nervous system viral clearance by promoting IL-10 and enhances demyelination | |
| ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
| JP2006180865A (ja) | マラリアペプチド | |
| EA199800746A1 (ru) | Способ генерации противовирусного иммунного ответа у человека или животного | |
| DK1093465T3 (da) | Fremgangsmåde til frembringelse eller forögelse af en T-cellerespons mod en målcelle ved brug af kompleks omfattende et HLA klasse I molekyle og et tilkoblingsorgan | |
| CU23235A1 (es) | POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA | |
| Yao et al. | Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine | |
| HUP0401585A2 (hu) | Fertőző, marhában előforduló, vírusos hasmenés vírusklónja | |
| ATE351904T1 (de) | Einem peptid aus antigen muc-1 entsprechende dns zur auslösung einer immunreaktion gegen tumorzellen | |
| Saeed et al. | Contemplating the importance of toll-like receptors I and II regarding human viral pathogenesis | |
| CO5650177A2 (es) | Constructos geneticos y composiciones que comprenden rre y cte y usos de estos | |
| Seighali et al. | Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies | |
| Jin et al. | The Epitope Basis of Embryonic Stem Cell‐Induced Antitumor Immunity against Bladder Cancer | |
| WO2001030989A3 (en) | Method for creating divergent populations of nucleic acid molecules and proteins | |
| Zeng et al. | DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseases | |
| Bowers | DNA and other technologies for HIV vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |